Stay updated on Regeneron Press Releases
Sign up to get notified when there's something new on the Regeneron Press Releases page.

Latest updates to the Regeneron Press Releases page
- Check2 days agoChange DetectedAdded two high-impact updates: Libtayo plus chemotherapy shows five-year survival gains in advanced NSCLC, and Regeneron reports two positive Phase 3 allergy trials. Removed older items: donation-matching CSR program and Dupixent BP approval news, shifting the page toward current progress and future pipeline.SummaryDifference100%
- Check10 days agoChange DetectedThe page now includes an updated presentation time for an upcoming investor conference by Regeneron, while a significant announcement regarding Dupixent's superiority in a clinical trial has been removed.SummaryDifference17%
- Check17 days agoChange DetectedThe webpage has added a significant announcement regarding Regeneron's positive trial results for a treatment related to Generalized Myasthenia Gravis, while removing a previous announcement about Dupixent's data presented at a conference.SummaryDifference15%
- Check24 days agoChange DetectedThe page now includes an FDA review period extension for EYLEA HD® (aflibercept) Injection, while a previous announcement regarding Regeneron's expansion of its obesity portfolio has been removed.SummaryDifference16%
- Check38 days agoChange DetectedThe page has added information about Regeneron's upcoming investor conference presentations while removing details about interim results from a clinical trial related to semaglutide.SummaryDifference14%
- Check45 days agoChange DetectedThe page has added a report on Regeneron's second quarter financial results for 2025 while removing a previous announcement regarding Libtayo's Phase 3 data.SummaryDifference14%
Stay in the know with updates to Regeneron Press Releases
Enter your email address, and we'll notify you when there's something new on the Regeneron Press Releases page.